

Licensing Opportunity (BioT-1313-UMG)

New animal model system for sporadic Alzheimer's Disease


Alzheimer's Disease (AD) is the main neurodegenerative disease worldwide affecting more than 15 Mill. people. It places a large social and financial burden on society due to the need of life-long intensive care. There are two forms of AD identified by researchers, sporadic AD (SAD) and familial autosomal dominant AD (genetic background).

Sporadic AD is the more common form, **accounting for 90-95% of cases**. Surprisingly, there is no animal model for the sporadic AD form available on the market.

Scientists of the University of Göttingen have now developed a **transgenic mouse model for sporadic Alzheimer's Disease (TBA83)**. This is the first mouse model without any mutations showing neurological deficits by transgenic over-expressing of a particular form of amyloid beta peptides. The neurological phenotype resembles that of mouse models with neurodegeneration.

Hallmarks

- **First AD animal model without any mutations.**
- No artificial or inherited familial mutations, **representing the sporadic and more common form of AD (SAD)**.
- **Current AD animal models** with mutations either from AD families or artificial mutations, **representing only 5-10% of AD cases**.
- SAD model system **based on Amyloidogenesis** by transgenic over-expressing of a naturally occurring form of amyloid beta peptides.
- Early development of **neurological deficits** at about 2-4 months:
 - **Neurodegeneration**, particularly in hippocampus.
 - **Learning, memory and behavioural deficits**.
- **Good and effective breeding.**
- **Excellent model for efficacy testing** of potential therapeutic approaches for AD.



Early manifestation of neurodegeneration: Inflammatory changes in hippocampus of a **2 months-old TBA83 mouse**. A+B: GFAP staining of reactive astrocytes in hippocampus, indicating early neurodegenerative events (GFAP: Glial Fibrillary Acidic Protein. Marker protein for astrocytes.).

We submitted an international patent application and are **looking for partners to license and commercialize our innovative technology**.